Document is current
Any future updates will be listed below
-
Authors
Alyaydin, Emyal
Parianos, Danaë
Hermes-Laufer, Julia
Nägele, Matthias P.
Castro, Liesa
Papathanasiou, Maria
Reinecke, Holger
Flammer, Andreas J.
-
Funding
Funding for this research was provided by:
University of Zurich
- License Information
-
More Information
Article History
Accepted: 1 November 2024
First Online: 8 November 2024
Declarations
:
: E. A. reports educational and training grant from the European Society of Cardiology (ESC), congress grants from the Heart Failure Association of the ESC, congress grants from the German Society of Cardiology and German Society of Internal Medicine, all unrelated to this article. M.P.N. reports speaker fees by AstraZeneca and Vifor Pharma unrelated to the article, consultancy fees by Boehringer Ingelheim and Pierre Fabre, and congress travel support by Pfizer, all unrelated to the article. H.R. reports personal fees from Daiichi Sankyo, Pfizer, MedUpdate, StreamedUp, DiaPlan, NeoVasc, Pluristem, NovoNordisk and Corvia. institutional grants from Pluristem, BMS, Pfizer, Bard and Biotronik. A.J.F. reports fees from Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius, Medtronic, MSD, Mundipharma, Novartis, NovoNordisk, Pierre Fabre, Pfizer, Roche, Vifor, and Zoll, as well as grant support by Novartis, AstraZeneca and Berlin Heart unrelated to this article. All other authors declare no conflict of interest.
